Identifying data |
Summary data |
||||||||
Source |
Year
|
Significant
cancer definition |
Detection
rate any cancer, SB (%) |
Detection
rate clinically significant cancer, SB (%) |
Patients
with clinically significant cancer detected by SB only (Missed by Tbx) (%) |
Patients
with clinically insignificant cancer detected by SB only (Missed by Tbx) (%) |
Detection
rate any cancer, TB (%) |
Detection
rate clinically significant cancer, TB (%) |
Patients
with clinically significant cancer detected by TB only (Missed by SB) (%) |
Da Rosa, et al. |
2014 |
Epstein |
29.2 |
16.7 |
10.53 |
25.00 |
36.11 |
23.61 |
36.84 |
Fiard,
et al. |
2013 |
Cancer volume ≥ 0.5 mL,
pathological stage ≥ pT3 or Gleason ≥ 3 + 4 |
43.3 |
33.3 |
9.09 |
66.67 |
36.67 |
33.33 |
9.09 |
Haffner,
et al. |
2010 |
Epstein |
52.3 |
42.7 |
5.22 |
100.00 |
42.52 |
42.52 |
4.82 |
Hu, et al. |
2014 |
Gleason ≥ 3 + 4 |
58.9 |
20.0 |
47.83 |
46.34 |
37.78 |
13.33 |
21.74 |
Kasivisvanathan,
et al. |
2013 |
Cancer core length ≥ 4 mm or
Gleason ≥ 3 + 4 |
79.1 |
62.1 |
20.77 |
63.64 |
65.93 |
56.59 |
13.08 |
Lawrence, et al. |
2014 |
Gleason ≥ 3 + 4 |
30.8 |
12.8 |
0.00 |
57.14 |
30.77 |
23.08 |
44.44 |
Mozer,
et al. |
2014 |
Cancer core length ≥ 4 mm or
Gleason ≥ 3 + 4 |
56.6 |
36.8 |
5.71 |
33.33 |
53.95 |
43.42 |
20.00 |
*Park, et al. |
2011 |
Gleason ≥ 3 + 3 |
27.3 |
27.3 |
30.77 |
N/A |
20.45 |
20.45 |
7.69 |
Pepe,
et al. |
2013 |
Gleason ≥ 3 + 3 |
35.9 |
35.9 |
18.75 |
N/A |
33.33 |
33.33 |
12.50 |
Pokorny,
et al. |
2014 |
NR |
56.5 |
35.4 |
13.89 |
82.35 |
44.39 |
41.70 |
26.85 |
Puech,
et al. |
2013 |
Cancer core length ≥ 3 mm or
Gleason ≥ 3 + 4 |
58.9 |
51.6 |
1.54 |
71.43 |
69.47 |
67.37 |
24.62 |
Quentin, et al. |
2014 |
Gleason ≥ 3 + 4 |
53.1 |
42.2 |
9.38 |
28.57 |
53.13 |
45.31 |
15.63 |
Radtke,
et al. |
2014 |
Gleason ≥ 3 + 4 |
65.8 |
34.7 |
12.79 |
43.75 |
56.63 |
38.27 |
20.93 |
Salami, et al. |
2014 |
Epstein |
48.6 |
30.7 |
6.94 |
68.42 |
52.14 |
47.86 |
40.28 |
Shakir,
et al. |
2014 |
Gleason ≥ 3 + 4 |
46.8 |
12.2 |
9.90 |
22.58 |
45.96 |
17.25 |
36.46 |
Somford,
et al. |
2013 |
Gleason ≥ 3 + 3 |
100.0 |
100.0 |
0.00 |
51.06 |
53.70 |
11.11 |
0.00 |
Sonn,
et al. |
2013 |
Epstein |
26.6 |
13.8 |
13.64 |
77.78 |
22.34 |
20.21 |
40.91 |
Wysock,
et al. |
2014 |
Gleason ≥ 3 + 4 |
55.2 |
32.8 |
12.00 |
64.29 |
40.30 |
32.84 |
12.00 |
*(targeted
was not performed in two pts bc systematic covered suspected cancer).